- PX 12
- KC7F2
- BAY 87-2243
- ML 228
- IOX2(Glycine)
- FG-4592 (ASP1517)
| DMOGCompetitive HIF-PH inhibitor, cell-permeable |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 98.00%
- COA (Certificate Of Analysis)
- MS (Mass Spectrometry)(Retest)
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
| Description | DMOG is a cell-permeable, competitive inhibitor of HIF-PH. | |||||
| Targets | HIF-PH | |||||
| IC50 | ||||||
| Cell experiment [1]: | |
Cell lines | B1 cells |
Preparation method | The solubility of this compound in DMSO is >8.8mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition | 1 mM, 2 hours |
Applications | DMOG upregulated phosphorylated p50 (S337) in peritoneal M. |
| Animal experiment [1]: | |
Animal models | BALB/c and C57BL/6 mice |
Dosage form | 8 mg/mouse, Intraperitoneal injection |
Application | DMOG had significantly increased survival in LPS-induced shock. DMOG treatment upregulated the expression of IL-10, specifically in the peritoneal B-1 cell population. Mice receiving DMOG treatment prior to surgery developed significant exacerbation of disease symptoms and significantly increased mortality rate. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1]. Hams E, Saunders S P, Cummins E P, et al. The hydroxylase inhibitor DMOG attenuates endotoxic shock via alternative activation of macrophages and IL-10 production by B-1 cells[J]. Shock (Augusta, Ga.), 2011, 36(3): 295. | |
DMOG Dilution Calculator
calculate
DMOG Molarity Calculator
calculate
| Cas No. | 89464-63-1 | SDF | Download SDF |
| Synonyms | N/A | ||
| Chemical Name | methyl 2-[(2-methoxy-2-oxoethyl)amino]-2-oxoacetate | ||
| Canonical SMILES | COC(=O)CNC(=O)C(=O)OC | ||
| Formula | C6H9NO5 | M.Wt | 175.14 |
| Solubility | ≥8.75mg/mL in DMSO | Storage | Store at -20°C |
| Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
IC50: 9.3 and 3.7 μM for hydroxyproline synthesis inhibition of embryonic chicken lung extracted from tissue and culture medium [1].
Dimethyloxalylglycine (DMOG) is an inhibitor of prolyl-4-hydroxylase domain (PHD) enzymes that regulate the stability of hypoxia-inducible factor (HIF). Localized tissue hypoxia is a feature of infection and inflammation, leading to the upregulation of the transcription factors HIF-1α and NF-κB via inhibition of oxygen sensing hydroxylase enzymes.
In vitro: DMOG acts to stabilize HIF-1a expression under normal oxygen tension in cultured cells at concentrations from 0.1 to 1 mmol/L [2].
In vivo: Pre-treatment with DMOG attenuates systemic LPS-induced activation of the NF-κB pathway. Furthermore, mice treated with DMOG had significantly increased survival in LPS-induced shock. In addition, in vivo DMOG treatment upregulates the expression of IL-10, specifically in the peritoneal B-1 cell population [3].
Clinical trial: Currently no clinical data are available.
References:[1] Baader E, Tschank G, Baringhaus KH, Burghard H, Günzler V. Inhibition of prolyl 4-hydroxylase by oxalyl amino acid derivatives in vitro, in isolated microsomes and in embryonic chicken tissues. Biochem J. 1994 Jun 1;300 ( Pt 2):525-30.[2] Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001 Apr 20;292(5516):468-72. [3] Hams E, Saunders SP, Cummins EP, O"Connor A, Tambuwala MT, Gallagher WM, Byrne A, Campos-Torres A, Moynagh PM, Jobin C, Taylor CT, Fallon PG. The hydroxylase inhibitor dimethyloxallyl glycine attenuates endotoxic shock via alternative activation of macrophages and IL-10 production by B1 cells. Shock. 2011 Sep;36(3):295-302.
